Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Xue HanYang-Kui GuShao-Long LiHao ChenMin-Shan ChenQing-Qing CaiHan-Xia DengMeng-Xuan ZuoJin-Hua HuangPublished in: Journal of cancer research and clinical oncology (2018)
In patients with HBV-related HCC, serum sPD-L1 concentrations were elevated, and positively correlated with tumor PD-L1 expression. Lower pre-treatment serum sPD-L1 levels were predictors of more favorable disease-free and overall survival. Serum sPD-L1 testing has a potential role in HBV-related HCC disease assessment, systemic therapy choices and survival prediction.